Developing a novel medical-grade microneedle patch to treat acne vulgaris

开发一种新型医用级微针贴片来治疗寻常痤疮

• 批准号: 10053162
• 金额: $ 43.99万
• 依托单位: IMPERIAL BIOSCIENCE LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10053162
• 关键词: Developing; novel; medical; grade; microneedle

Imperial Bioscience aims to be the first-to-market with their microneedle drug delivery product for medical use. Microneedle-mediated delivery is defined as the non-invasive delivery of medications through the skin surface. This is an alternative to hypodermic needles, which provides enhanced patient compliance. Expanded microneedle patch technology will become a highly valuable tool for delivering various pharmaceuticals with ease but without provoking skin irritation and side effects.Imperial Bioscience targets acne vulgaris. This project aims to understand the safety and efficacy of anti-acne drugs applied with microneedle technology in treating types of acne vulgaris that are historically considered less responsive and/or with side effects to oral medications. Work will develop a robust and stable platform for a novel means for delivering drug molecules directly into the skin where associated skin concerns originated; provide critical analysis of preclinical data for interactions of the cell types within the skin and mapping out safety and efficacy profile of microneedle technology associated with human skin inflammatory disorder of acne; leading to selection of a lead candidate for clinical study.

Imperial Bioscience的目标是成为市场上第一个推出医用微针药物输送产品的公司。微针介导的给药被定义为药物通过皮肤表面的非侵入性给药。这是皮下注射针的一种替代方案，可以提高患者的依从性。扩展微针贴片技术将成为一种非常有价值的工具，可以轻松地输送各种药物，而不会引起皮肤刺激和副作用。帝国生物科学针对的是寻常痤疮。该项目旨在了解应用微针技术的抗痤疮药物在治疗历来被认为对口服药物反应较小和/或有副作用的寻常型痤疮中的安全性和有效性。工作将为一种新的方法开发一个强大而稳定的平台，将药物分子直接输送到引发相关皮肤担忧的皮肤；为皮肤内细胞类型的相互作用提供关键的临床前数据分析，并绘制与人类皮肤炎症性疾病痤疮相关的微针技术的安全性和有效性概况；导致选择临床研究的主要候选对象。